An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures

Grace Collord, Patrick Tarpey, Natalja Kurbatova, Inigo Martincorena, Sebastian Moran, Manuel Castro, Tibor Nagy, Graham Bignell, Francesco Maura, Matthew D Young, Jorge Berna, Jose M C Tubio, Chris E McMurran, Adam M H Young, Mathijs Sanders, Imran Noorani, Stephen J Price, Colin Watts, Elke Leipnitz, Matthias KirschGabriele Schackert, Danita Pearson, Abel Devadass, Zvi Ram, V Peter Collins, Kieren Allinson, Michael D Jenkinson, Rasheed Zakaria, Khaja Syed, C Oliver Hanemann, Jemma Dunn, Michael W McDermott, Ramez W Kirollos, George S Vassiliou, Manel Esteller, Sam Behjati, Alvis Brazma, Thomas Santarius, Ultan McDermott

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
152 Downloads (Pure)


Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable recurrences and dismal outcomes. Here, we present an integrated analysis of the whole genome, transcriptome and methylation profiles of primary and recurrent anaplastic meningioma. A key finding was the delineation of distinct molecular subgroups that were associated with diametrically opposed survival outcomes. Relative to lower grade meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex genes, which were confined to the poor prognosis subgroup. Aggressive disease was further characterised by transcriptional evidence of increased PRC2 activity, stemness and epithelial-to-mesenchymal transition. Our analyses discern biologically distinct variants of anaplastic meningioma with prognostic and therapeutic significance.

Original languageEnglish
Article number13537
JournalScientific Reports
Issue number1
Publication statusPublished - 10 Sept 2018


Dive into the research topics of 'An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures'. Together they form a unique fingerprint.

Cite this